Ofer Merimsky
- 4.5 良い • 169 レビュー
- 41年の経験
- 認定:
- イスラエル, テルアビブ, Sourasky Medical Center (Ichilov)
スラスキー医療センターの骨肉腫専門医。整形外科腫瘍学において41 年以上の経験を持つ。
- 2000年より軟部組織・骨腫瘍科部長
- パリのギュスターヴ・ルシー研究所にてフェローシップ修了
- ESMO(欧州臨床腫瘍学会)肉腫研究部門の教員
- 骨腫瘍治療に関する多数の論文を発表
- がん臨床試験の倫理委員会を統括
- 続きを読む
スラスキー医療センターの骨肉腫専門医。整形外科腫瘍学において41 年以上の経験を持つ。
オンダー・スルジット医師は、オプティメッド国際病院の一般外科教授です。先端医療技術トレーニングセンター(ITEM)の外科インストラクターでもあります。スルジット医師は、がん、肥満、複雑な消化器疾患を治療しています。減量や腫瘍切除のために腹腔鏡下手術技術を適用しています。
ムスタファ・ソラク医師は、複雑な癌の症例を専門としており、ハジェテペ大学およびMDアンダーソンがんセンターで研修を受けました。
シュロミ・コンスタンティーニ教授は、ソウラスキー医療センターで小児および成人の骨切除を専門とする主要な脳神経外科医です。
ドロール・レヴィン医師は、イスラエル有数の病院であるソラスキー医療センターにて、小児骨腫瘍(肉腫)を専門としています。
ダン・フリス教授は、ソラスキー医療センター(イヒロフ)の腫瘍学を専門としており、骨切除術の症例において豊富な専門知識を有しています。
シーヒルンウォン医師はイントララット病院の診断放射線科を専門としており、骨切除術のための正確な画像診断を提供しています。
スターンハイム医師は肉腫治療を専門としており、軍事医学および外科腫瘍学における功績により数々の賞を受賞しています。
タフシン・オザトリ医師は、イスティニエ・リヴ大学病院にて乳がん、肺がん、消化器がんの治療を専門としています。
トゥンジェル医師は整形外科腫瘍学を専門とし、イブン・イ・シナ病院およびアジバデム医学部で高度な研修を受けています。
ムスタファ・セルカン・アレムダル医師は、メディカルパーク・アンタルヤ病院コンプレックスの臨床腫瘍医です。複雑な固形腫瘍および血液がんの治療を専門としています。アレムダル医師は、アクデニズ大学で医学の学位を取得し、腫瘍学のフェローシップを修了しました。トルコ臨床腫瘍学会の活動的なメンバーです。
アイリス・クヴェンツェル博士は、シェバ医療センターの小児血液腫瘍科医であり、骨髄移植の専門家です。エドモンド&リリー・サフラ小児病院にて、ユーイング肉腫や骨肉腫などの小児肉腫を治療しています。クヴェンツェル博士は、複雑な小児がんに対して標的療法と細胞治療を統合した治療を行っています。また、テルアビブ大学医学部の教員も務めています。
エイタン・アハロン・ベン=アミ医師は、イスラエルのシェバ医療センターで腫瘍学部門を率いています。ダナ・ファーバー癌研究所で肉腫および骨腫瘍学を専門としました。ベン=アミ医師は、がん研究を推進するためにシェバ臨床研究機構を設立しました。希少な骨腫瘍や軟部組織肉腫を個別化プロトコルで治療しています。
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993,27(6):361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996,30(8):521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998,14(3):189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000,34(5):335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002,36(7):612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004,20(9):1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006,40(8):876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008,28(10):856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
小児整形外科・外傷外科医、外科腫瘍学を専門とする
15年の経験
アパク医師は小児血液学および腫瘍学を専門とし、26 年以上の経験を持ち、骨髄移植と白血病の化学療法に重点を置いています。
アブドラ・サキン教授(Prof. Dr. Abdullah Sakin)は、腫瘍内科の教授です。肺がん、乳がん、消化器がん、泌尿器がん、婦人科がん、頭頸部がん、悪性黒色腫(メラノーマ)などの固形腫瘍を専門としています。
科学的根拠に基づいた個別化医療を提供しています。治療法には、化学療法、分子標的療法、免疫療法、ホルモン療法、精密腫瘍学(プレシジョン・オンコロジー)が含まれます。200本以上の科学論文を執筆しており、国際的な臨床研究にも積極的に参加しています。これらの活動は、患者中心のがん医療の発展に寄与しています。
Gül Alço教授は、約27年の経験を持つ放射線腫瘍医です。乳がん、肺がん、前立腺がん、消化器がん、婦人科がん、中枢神経系腫瘍、頭頸部がん、軟部組織腫瘍、骨腫瘍の放射線治療を行っています。
専門分野は、適応放射線治療とラジオサージャリー(放射線外科)です。高度な放射線技術を駆使し、患者中心の多職種連携環境において、個別化された科学的根拠に基づくケアを提供しています。
| 順位 | 医師 | 経験 | 適合する方 | 特色 | クリニックと所在地 | 診察 |
|---|---|---|---|---|---|---|
| #1 | 41年の経験 | 複雑な骨肉腫の症例 | 骨腫瘍を専門とし、イスラエル有数の肉腫ユニットを運営。ESMOの教員であり、パリで高度な技術のフェローシップ研修を修了。 | イスラエル | から $950 | |
| #2 | 20年の経験 | 複雑な癌の症例 | MDアンダーソンがんセンターおよびハジェテペ大学がん研究所で研修を受け、複数の影響度の高い癌を専門としています。 | トルコ | から $100 | |
| #3 | 42年の経験 | 小児の骨構造障害 | 高度な顕微鏡下手術技術を用いた先天性および新生児の骨疾患を専門とする。受賞歴のある研究者であり、複数の権威ある脳神経外科協会の会員。 | イスラエル | お問い合わせください | |
| #4 | 41年の経験 | 小児骨肉腫 | 小児骨腫瘍のみを専門とし、イタリアの著名なリッツォーリ研究所で研修を積んでいます。イスラエルのトップ病院で肉腫治療プログラムを主導しています。 | イスラエル | お問い合わせください | |
| #5 | 40年の経験 | 複雑な骨切除術 | 骨切除に重点を置いた腫瘍学の専門家。イスラエルのトップクラスの医療機関であるソラスキー医療センターの教授。 | イスラエル | お問い合わせください | |
| #6 | 21年の経験 | 正確な画像診断 | 正確な画像解釈に重点を置いた診断放射線科の専門医。プリンス・オブ・ソンクラー大学認定。 | タイ | お問い合わせください | |
| #7 | 28年の経験 | 複雑な肉腫症例 | 肉腫に対する四肢温存術を専門とし、外科腫瘍学における卓越した業績で表彰されています。主要な筋骨格腫瘍学会の会員です。 | イスラエル | お問い合わせください | |
| #8 | 2016年の経験 | 乳がん、肺がん、消化器がん | 乳がん、肺がん、消化器がんの専門医であり、トルコのトップクラスの病院での経験が豊富。2016年より准教授。 | トルコ | お問い合わせください | |
| #9 | 17年の経験 | 複雑な骨腫瘍 | 骨切除技術の高度な研修を受けた整形外科腫瘍学の専門家。TOTBIDを含む複数の専門学会の会員。 | トルコ | お問い合わせください | |
| #10 | 26年の経験 | 小児骨髄移植 | CAR-T細胞療法の専門知識を持ち、小児血液腫瘍科を率いる。小児腫瘍学の治療法に関する広範な出版物がある。 | トルコ | お問い合わせください |